Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study

• Main Authors: Stefano Mazza (Author), Nicole Piazza O. Sed (Author), Francesco Simone Conforti (Author), Alberto Fascì (Author), Alessandro Rimondi (Author), Beatrice Marinoni (Author), Valentina Casini (Author), Chiara Ricci (Author), Francesca Munari (Author), Lorena Pirola (Author), Pietro Invernizzi (Author), Carlo Girelli (Author), Guido Lupinacci (Author), Luca Pastorelli (Author), Flaminia Cavallaro (Author), Luca Ferraris (Author), Alice Colucci (Author), Arnaldo Amato (Author), Gian Eugenio Tontini (Author), Maurizio Vecchi (Author), Gionata Fiorino (Author), Flavio Caprioli (Author)
• Formato: Livro
• Publicado em: Wiley, 2022-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT‐P13 and subsequently to SB2 (double switch) in pati...